Successful desensitization to high dose rituximab for a child with nephrotic syndrome – The first report in the literature

Konstantinos Kakleas *, Kerrie Kirk, Dave Harris, and Angela Hall
Paediatric Department, Leicester Royal Infirmary, Leicester, UK

ABSTRACT

Rituximab is a chimeric monoclonal antibody, which is mainly used in the treatment of lymphomas and autoimmune disorders, but also has been recently approved for the treatment of nephrotic syndrome. The treatment dose is between 375 mg/m² and 750 mg/m². Rituximab has been associated with hypersensitivity reactions, which can be classified either into early and late infusion-associated adverse reactions. Different desensitization protocols have been described in adult patients who require rituximab, however, there is a limited experience in children and in patients with nephrotic syndrome. Additionally, all the published protocols for adults and children are based on the low-dose rituximab desensitization. We report the first case in the literature of desensitization to high-dose rituximab in a child with nephrotic syndrome, suggesting a well-tolerated protocol adjusted on the high dose and the clinical reaction to the drug. This protocol can be used for children with nephrotic syndrome and severe reaction that require 750 mg/m² of rituximab.

Keywords: Rituximab; High dose; Child; Desensitization; Nephrotic syndrome

INTRODUCTION

Rituximab is a monoclonal antibody used in the treatment of lymphomas and autoimmune disorders [1, 2]. It is also indicated for nephrotic syndrome, although not formally approved [3, 4]. The treatment dose is between 375 mg/m² and 750 mg/m² [5].

Rituximab is a well-tolerated medication for children with nephrotic syndrome; however, side-effects do present. The commonest side-effect is infusion-associated adverse reaction manifesting with fever, headache, rigor, nausea, vomiting, hypotension, tachycardia, and rash. This reaction is attributed to cytokine release of tumor necrosis factor (TNF)-α and interleukin (IL)-6 [6]. Immediate hypersensitivity IgE-mediated reactions have also been reported [7]. The risk increases with higher doses of rituximab and increased comorbidities, for example azathioprine treatment. Death has been reported in approximately 5% of patients [8-10].

Infusion-associated adverse reactions can be prevented with the use of H1-antihistamines, paracetamol, and previously with ranitidine, before commencing the infusion, along
with a slower infusion rate. Where immediate hypersensitivity reactions (HRs) occur, the recommended advice is avoidance of the medication or desensitization if there is no alternative drug. We report the first case in the literature of successful desensitization to high dose rituximab for a child with nephrotic syndrome.

**CASE REPORT**

A 10-year-old girl was referred to the pediatric allergy team for rituximab desensitization. Rituximab therapy at a dose of 375 mg/m² had been tried previously. When the patient was given the initial infusion of rituximab, despite full pretreatment, the 3rd increase in the infusion rate (3.5 mg/kg/hr) resulted in her reporting throat tightness. The infusion was paused and symptoms resolved spontaneously. The infusion was then restarted at the previous uneventful slower rate, remaining at that rate for the remainder of the infusion. The following night she complained of severe headache resembling migraine, but this resolved.

The renal team decided to treat the patient with higher 750 mg/m² dose. When the patient presented for the second rituximab infusion using the higher dose of 1,110 mg (weight, 52 kg; body surface area [BSA], 1.45 m²), she was premedicated with oral paracetamol, intravenous chlorphenamine, methylprednisolone, and hydrocortisone. The rituximab infusion was stopped at 34 mL/hr due to symptoms of throat pruritus, tongue swelling, difficulty breathing, and wheeze. The reaction was treated with oral H1-antihistamine medication and intravenous hydrocortisone. Decision was made to discontinue the infusion and desensitize the patient.

The allergy team chose to perform a 15-step desensitization protocol consisting of 3 solutions; dilutions of 1:100, 1:10, 1:1 to administer a total dose of 1,120 mg (weight, 54 kg; BSA, 1.49 m²) (Table 1).

**Table 1.** Desensitization protocol to rituximab

| Stock solution | Dilution | Volume | Fluid volume to be removed | Volume of Rituximab to be added | Final concentration |
|----------------|----------|--------|-----------------------------|---------------------------------|--------------------|
| A              | 1/100    | 250 mL | Nil                         | 1 mL (10 mg)                    | 0.04 mg/mL         |
| B              | 1/10     | 250 mL | 10 mL                       | 10 mL (100 mg)                  | 0.4 mg/mL          |
| C              | 1/1      | 250 mL | 100 mL                      | 100 mL (1,000 mg)               | 4 mg/mL            |

| Step | Solution | Rate | Time per step | Volume per step | Dose/step | Cumulative dose |
|------|----------|------|---------------|-----------------|-----------|-----------------|
| 1    | A        | 2 mL/hr | 15 min    | 0.5 mL           | 0.02 mg   | 0.02 mg         |
| 2    | A        | 4 mL/hr | 15 min    | 1 mL             | 0.04 mg   | 0.06 mg         |
| 3    | A        | 10 mL/hr| 15 min    | 2.5 mL           | 0.1 mg    | 0.16 mg         |
| 4    | A        | 20 mL/hr| 15 min    | 5 mL             | 0.2 mg    | 0.36 mg         |
| 5    | B        | 4 mL/hr | 15 min    | 1 mL             | 0.4 mg    | 0.76 mg         |
| 6    | B        | 10 mL/hr| 15 min    | 2.5 mL           | 1 mg      | 1.76 mg         |
| 7    | B        | 20 mL/hr| 15 min    | 5 mL             | 2 mg      | 3.76 mg         |
| 8    | B        | 40 mL/hr| 15 min    | 10 mL            | 4 mg      | 7.76 mg         |
| 9    | C        | 10 mL/hr| 15 min    | 2.5 mL           | 10 mg     | 17.76 mg        |
| 10   | C        | 20 mL/hr| 15 min    | 5 mL             | 20 mg     | 37.76 mg        |
| 11   | C        | 40 mL/hr| 15 min    | 10 mL            | 40 mg     | 77.76 mg        |
| 12   | C        | 60 mL/hr| 15 min    | 15 mL            | 60 mg     | 137.76 mg       |
| 13   | C        | 80 mL/hr| 15 min    | 20 mL            | 80 mg     | 217.76 mg       |
| 14   | C        | 160 mL/hr| 15 min  | 40 mL            | 160 mg    | 377.76 mg       |
| 15   | C        | 160 mL/hr| 70 min  | 185.5 mL         | 742 mg    | 1,120 mg        |

Total drug dose: 1,120 mg (Truxima 10 mg/mL).
Premedication: oral cetirizine 10 mg, oral paracetamol 500 mg, and intravenous methylprednisolone 90 mg approximately 30 minutes prior to commencing the desensitization infusion. In addition, she received 2 doses of montelukast, 5 mg the night before and 5 mg on the morning of the procedure.
The patient was premedicated with oral cetirizine, paracetamol, and intravenous methylprednisolone. Additionally, she received 2 doses of montelukast, 5 mg the night before and on the morning of the procedure.

The patient did not report any symptoms and was discharged following 2 hours observation after the end of the infusion.

**DISCUSSION**

To our knowledge, this is the first successful desensitization of a pediatric patient to the high 750 mg/m$^2$ dose of rituximab required for the management of nephrotic syndrome.

From previous studies, the incidence of HRs to rituximab is 25%–78% [11]. Early infusion-associated adverse reactions (EIAR) such as fever, rigors, nausea, vomiting, hypotension, rhinitis, bronchoconstriction, angioedema, urticaria, and flushing can be caused by an IgE-mediated mechanism or cytokine release syndrome and production of TNF-α and IL-6 [12]. The late infusion-associated adverse reactions may be similar to the EIAR, but also include serum sickness, Stevens-Johnson syndrome, toxic epidermal necrolysis [13]. Our patient has developed symptoms consistent with EIAR. Symptoms from the respiratory system have been reported by up to 60% of patients who receive rituximab infusion [11].

Our team did not perform skin-prick testing (SPT) or intradermal testing (IDT) as there was urgency for patient to receive the infusion and symptoms were consistent with IgE-mediated reaction. The relevance of SPT/IDT in the management of rituximab hypersensitivity is still under investigation [14]. A recent study demonstrated that the status of the SPT and/or IDT did not correlate with desensitization outcome [11].

Previous studies have published desensitization protocols for children with lymphoproliferative syndrome, opsoclonus myoclonus, and B-cell lymphomas [15, 16]. The cumulative dose in these studies varied from 285–600 mg. One study has included an adolescent with steroid-sensitive nephrotic syndrome, who needed the standard 375-mg/m$^2$ dose [16].

We have created a protocol using 15 steps based on the history of a previous severe reaction to rituximab, in accordance with a recently published guideline [17]. The presence of bronchospasm and wheeze is considered as severe reaction. The protocol started at a dilution of 1:50,000 and, comparable with other protocols, the concentration was doubled at each step, with small adjustments for cost-effective medication use. Previous published protocols have suggested that in pediatric rituximab desensitization, the rate steps should not exceed 0.5 mg/kg/hr and the final infusion rate not be greater than 2 mg/kg/hr [16]. Due to practical reasons and size of the overall dose, the final rate was 6.92 mg/kg/hr and the rate increases were more than 0.5 mg/kg/hr but only during the third solution of our protocol, maintaining doubling of doses at each increment. Despite these modifications, the patient tolerated the desensitization. This highlights the application of using standard desensitization recommendations of doubling the dose at each stage should be used for children. It is a practical approach for desensitization to rituximab high dose. Our protocol is in accordance with published pediatric protocols for rituximab using only 3 dilutions irrespective of the number of steps. This is in contrast to the 16-step (4 dilutions) and 20-step (5 dilutions) protocols utilised in adults [15, 16, 18].
In comparison to other pediatric protocols, the allergy team used montelukast. The use of montelukast may have been beneficial since the patient’s reaction had resulted in bronchoconstriction; montelukast can prevent this as seen in studies of asthma [19]. Our team recommends the regular use of montelukast in the desensitization protocol.

We report the first case of desensitization to high dose rituximab in a child with nephrotic syndrome, suggesting a well-tolerated protocol adjusted on the high dose and the clinical reaction to the drug.

REFERENCES

1. Bingham CO 3rd, Looney RJ, Deodhar A, Halsey N, Greenwald M, Cooding C, Trzaskoma B, Martin F, Agarwal S, Kelman A. Immunization responses in rheumatoid arthritis patients treated with rituximab: results from a controlled clinical trial. Arthritis Rheum 2010;62:64-74.

2. Hamlin PA, Satram-Hoang S, Reyes C, Hoang KQ, Guduru SR, Skettino S. Treatment patterns and comparative effectiveness in elderly diffuse large B-cell lymphoma patients: a surveillance, epidemiology, and end results-medicare analysis. Oncologist 2014;19:1249-57.

3. Taha R, El-Haddad H, Almuallim A, Alshaikhi F, Obaid E, Almoallim H. Systematic review of the role of rituximab in treatment of antineutrophil cytoplasmic autoantibody-associated vasculitis, hepatitis C virus-related cryoglobulinemic vasculitis, Henoch-Schönlein purpura, ankylosing spondylitis, and Raynaud’s phenomenon. Open Access Rheumatol 2017;9:2014.

4. Kallash M, Smoyer WE, Mahan JD. Rituximab use in the management of childhood nephrotic syndrome. Front Pediatr 2019;7:178.

5. Roccatello D, Sciascia S, Di Simone D, Solfitetti L, Naretto C, Fenoglio R, Baldovino S, Menegatti E. New insights into immune mechanisms underlying response to Rituximab in patients with membranoproliferative nephropathy: a prospective study and a review of the literature. Autoimmun Rev 2016;15:529-38.

6. Tony HP, Burmester G, Schulze-Koops H, Grunke M, Henes J, Kötter I, Haas J, Unger L, Lowrie S, Haubitz M, Fischer-Betz R, Chehab G, Rubbert-Roth A, Specker C, Weinerth J, Holle J, Müller-Ladner U, König R, Fiehn C, Burgwinkel P, Budde K, Sörensen H, Meurer M, Aringer M, Kiesier B, Erfurt-Berge C, Stecher A, Schimmer B, Schwarting U, Herl M, Stadler R, Schwarzwald-Eywill M, Wasserberg S, Fleck M, Metzler C, Zetl U, Westphal J, Heitmann S, Herzog AL, Wiendl H, Jakob W, Schmidt E, Freiwegel K, Dörner T; GRAID investigators. Safety and clinical outcomes of rituximab therapy in patients with different autoimmune diseases: experience from a national registry (GRAID). Arthritis Res Ther 2011;13:R75.
11. Wong JT, Long A. Rituximab hypersensitivity: evaluation, desensitisation, and potential mechanisms. J Allergy Clin Immunol Pract 2017;5:1564-71.

12. Castells MC, Tennant NM, Sloane DE, Hsu FI, Barrett NA, Hong DI, Laidlaw TM, Legere HJ, Nallamshetty SN, Palis RJ, Rao JJ, Berlin ST, Campos SM, Matulonis UA. Hypersensitivity reactions to chemotherapy: outcomes and safety of rapid desensitization in 413 cases. J Allergy Clin Immunol 2008;122:574-80.

13. Kamei K, Ogura M, Sato M, Ito S, Ishikura K. Infusion reactions associated with rituximab treatment for childhood-onset complicated nephrotic syndrome. Pediatr Nephrol 2018;33:1013-8.

14. Hsu Blatman KS, Castells MC. Desensitizations for chemotherapy and monoclonal antibodies: indications and outcomes. Curr Allergy Asthma Rep 2014;14:453.

15. Dilley M, Lee JP, Pharm D, Platt CD, Broyles AD. Rituximab desensitisation in Pediatric patients: results of a case series. Pediatr Allergy Immunol Pulmonol 2016;29:91-4.

16. Cansever M, Ozcan A, Dursun I, Unal E, Tahan F. Successful rapid desensitisation of two teenagers with rituximab hypersensitivity. J Clin Diagn Res 2019;13:SD01-3.

17. Yang B, Castells MC. Rituximab hypersensitivity and desensitization: a personalized approach to treat cancer and connective tissue diseases. Ann Allergy Asthma Immunol 2019;123:11-5.

18. Picard M, Galvão VR. Current knowledge and management of hypersensitivity reactions to monoclonal antibodies. J Allergy Clin Immunol Pract 2017;5:600-9.

19. Philip G, Villarán C, Pearlman DS, Loeys T, Dass SB, Reiss TF. Protection against exercise-induced bronchoconstriction two hours after a single oral dose of montelukast. J Asthma 2007;44:213-7.